KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Assets: 2010-2024

Historic Non-Current Assets for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $42.6 million.

  • Nektar Therapeutics' Non-Current Assets fell 6.96% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year decrease of 6.96%. This contributed to the annual value of $42.6 million for FY2024, which is 36.79% down from last year.
  • According to the latest figures from FY2024, Nektar Therapeutics' Non-Current Assets is $42.6 million, which was down 36.79% from $67.3 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Non-Current Assets ranged from a high of $400.8 million in FY2020 and a low of $42.6 million during FY2024.
  • Its 3-year average for Non-Current Assets is $91.5 million, with a median of $67.3 million in 2023.
  • Data for Nektar Therapeutics' Non-Current Assets shows a maximum YoY tumbled of 59.10% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Non-Current Assets stood at $400.8 million in 2020, then dropped by 19.75% to $321.6 million in 2021, then crashed by 48.81% to $164.6 million in 2022, then plummeted by 59.10% to $67.3 million in 2023, then crashed by 36.79% to $42.6 million in 2024.